A 67-year-old woman has been admitted to same-day surgery and the nurse at the facility is conducting medication reconciliation. The nurse notes that the woman has recently been taking Tamoxifen. What condition would the nurse anticipate seeing a history of in the client's medical record?

Choice A rationale Tamoxifen is a selective estrogen receptor modulator (SERM). While it has been studied in colon cancer, its primary and well-established use is in the treatment of estrogen receptor-positive (ER-positive) breast cancer. It works by blocking the effects of estrogen on breast tissue cells, thereby inhibiting their growth and proliferation. It is not the standard primary therapy for colon cancer. Choice B rationale Tamoxifen is the medication of choice for the hormonal treatment of estrogen receptor-positive (ER-positive) breast cancer in both pre- and post-menopausal women. It acts as an antagonist, competitively binding to estrogen receptors in breast tissue, which prevents estrogen from stimulating cancer cell growth, thus inhibiting the proliferation of malignant cells. Choice C rationale Malignant melanoma, a type of skin cancer, is primarily treated with surgery, immunotherapy (e.g., checkpoint inhibitors), and targeted therapy (e.g., BRAF inhibitors) for specific gene mutations. Hormonal therapy like Tamoxifen does not play a role in the standard treatment protocol for malignant melanoma, as this cancer is not typically hormone-driven. Choice D rationale The vast majority of cervical cancers are caused by the human papillomavirus (HPV) and are typically treated with surgery, radiation, and chemotherapy. Cervical cancer is not typically an estrogen-driven cancer, and thus Tamoxifen is not a routine or primary part of the treatment regimen for this specific gynecologic malignancy.